Moderate Pain - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Moderate Pain - Pipeline Review, H1 2015', provides an overview of the Moderate Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Moderate Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Moderate Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Moderate Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Moderate Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Moderate Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Moderate Pain Overview 8 Therapeutics Development 9 Pipeline Products for Moderate Pain - Overview 9 Pipeline Products for Moderate Pain - Comparative Analysis 10 Moderate Pain - Therapeutics under Development by Companies 11 Moderate Pain - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Moderate Pain - Products under Development by Companies 16 Moderate Pain - Companies Involved in Therapeutics Development 18 A. Menarini Industrie Farmaceutiche Riunite Srl 18 Acura Pharmaceuticals, Inc. 19 Egalet Corporation 20 KemPharm, Inc. 21 Laboratorios Del Dr. Esteve S.A. 22 Lumosa Therapeutics Co., Ltd. 23 Nektar Therapeutics 24 Pain Therapeutics, Inc. 25 Pfizer Inc. 26 Relmada Therapeutics, Inc. 27 Trevena, Inc. 28 Moderate Pain - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 38 (acetaminophen + oxycodone hydrochloride) IR - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 (benzhydrocodone hydrochloride + acetaminophen) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 (celecoxib + tramadol hydrochloride) - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 (dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 (oxycodone hydrochloride + naltrexone) ER - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 buprenorphine hydrochloride ER - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Egalet-003 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ELS-130 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 hydromorphone hydrochloride IR - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 levorphanol tartrate ER - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 LT-1001 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 methadone IR - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 morphine sulfate ER - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 morphine sulfate IR - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 NKTR-181 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 NKTR-194 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 oxycodone hydrochloride ER - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 oxycodone hydrochloride ER - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 oxymorphone hydrochloride - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 PTI-202 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 PTI-721 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 tramadol hydrochloride IR - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 TRV-734 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Moderate Pain - Recent Pipeline Updates 65 Moderate Pain - Dormant Projects 74 Moderate Pain - Discontinued Products 75 Moderate Pain - Product Development Milestones 76 Featured News & Press Releases 76 Mar 04, 2014: KemPharm Expands Global Intellectual Property Estate for KP201 76 Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-001 76 Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-002 for Moderate to Severe Pain 76 Appendix 78 Methodology 78 Coverage 78 Secondary Research 78 Primary Research 78 Expert Panel Validation 78 Contact Us 78 Disclaimer 79
List of Tables Number of Products under Development for Moderate Pain, H1 2015 9 Number of Products under Development for Moderate Pain - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Comparative Analysis by Late Stage Development, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Development by Companies, H1 2015 (Contd..1) 17 Moderate Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 18 Moderate Pain - Pipeline by Acura Pharmaceuticals, Inc., H1 2015 19 Moderate Pain - Pipeline by Egalet Corporation, H1 2015 20 Moderate Pain - Pipeline by KemPharm, Inc., H1 2015 21 Moderate Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 22 Moderate Pain - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2015 23 Moderate Pain - Pipeline by Nektar Therapeutics, H1 2015 24 Moderate Pain - Pipeline by Pain Therapeutics, Inc., H1 2015 25 Moderate Pain - Pipeline by Pfizer Inc., H1 2015 26 Moderate Pain - Pipeline by Relmada Therapeutics, Inc., H1 2015 27 Moderate Pain - Pipeline by Trevena, Inc., H1 2015 28 Assessment by Monotherapy Products, H1 2015 29 Assessment by Combination Products, H1 2015 30 Number of Products by Stage and Target, H1 2015 32 Number of Products by Stage and Mechanism of Action, H1 2015 34 Number of Products by Stage and Route of Administration, H1 2015 36 Number of Products by Stage and Molecule Type, H1 2015 37 Moderate Pain Therapeutics - Recent Pipeline Updates, H1 2015 65 Moderate Pain - Dormant Projects, H1 2015 74 Moderate Pain - Discontinued Products, H1 2015 75
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.